Symbols / LXEO Stock $5.85 -2.66% Lexeo Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
LXEO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. R. Nolan Townsend M.B.A.
Exch · Country NGM · United States
Market Cap 433.41M
Enterprise Value 259.53M
Income -99.96M
Sales —
FCF (ttm) -62.60M
Book/sh 3.38
Cash/sh 2.45
Employees 59
Insider 10d —
IPO Nov 03, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.46
PEG —
P/S —
P/B 1.73
P/C —
EV/EBITDA -2.39
EV/Sales —
Quick Ratio 10.81
Current Ratio 11.21
Debt/Eq 3.20
LT Debt/Eq —
EPS (ttm) -1.81
EPS next Y -1.31
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-30
ROA -32.86%
ROE -55.00%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 74.09M
Shs Float 41.44M
Insider Own 0.77%
Instit Own 119.27%
Short Float 18.02%
Short Ratio 13.10
Short Interest 12.50M
52W High 10.99
vs 52W High -46.77%
52W Low 2.43
vs 52W Low 140.74%
Beta 2.00
Impl. Vol. 39.45%
Rel Volume 1.03
Avg Volume 909.26K
Volume 940.45K
Target (mean) $19.64
Tgt Median $19.00
Tgt Low $10.00
Tgt High $30.00
# Analysts 11
Recom None
Prev Close $6.01
Price $5.85
Change -2.66%
About

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.64
Mean price target
2. Current target
$5.85
Latest analyst target
3. DCF / Fair value
$-15.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.85
Low
$10.00
High
$30.00
Mean
$19.64

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-13 main Chardan Capital Buy → Buy $17
2026-01-13 main HC Wainwright & Co. Buy → Buy $10
2025-12-18 init Raymond James — → Strong Buy $25
2025-12-11 main Chardan Capital Buy → Buy $17
2025-12-01 init Cantor Fitzgerald — → Overweight $19
2025-11-20 init Cantor Fitzgerald — → Overweight $19
2025-11-06 main Chardan Capital Buy → Buy $17
2025-10-21 main HC Wainwright & Co. Buy → Buy $13
2025-10-15 init Guggenheim — → Buy $30
2025-10-07 main Chardan Capital Buy → Buy $17
2025-10-07 main Leerink Partners Outperform → Outperform $20
2025-10-07 main HC Wainwright & Co. Buy → Buy $15
2025-08-15 main Chardan Capital Buy → Buy $15
2025-08-15 main Leerink Partners Outperform → Outperform $9
2025-08-15 main HC Wainwright & Co. Buy → Buy $9
2025-07-31 init Oppenheimer — → Outperform $20
2025-05-30 main JP Morgan Overweight → Overweight $10
2025-05-16 main HC Wainwright & Co. Buy → Buy $15
2025-05-13 main Chardan Capital Buy → Buy $20
2025-05-12 main Leerink Partners Outperform → Outperform $16
News
RSS: Latest LXEO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 TOWNSEND RICHARD NOLAN Chief Executive Officer — 55,000 $5.69 $313,137
2026-03-13 TOWNSEND RICHARD NOLAN Chief Executive Officer — 2,623 $6.66 $17,469
2026-03-13 OTERO JOSE MANUEL Chief Operating Officer — 5,930 $6.66 $39,494
2026-02-18 TOWNSEND RICHARD NOLAN Chief Executive Officer — 10,173 $6.38 $64,924
2026-02-18 OTERO JOSE MANUEL Chief Operating Officer — 3,016 $6.40 $19,294
2026-02-13 BHALLA NARINDER PAL M.D. Officer — 49,500 $0.00 $0
2026-02-04 TOWNSEND RICHARD NOLAN Chief Executive Officer — 161,665 $0.00 $0
2026-02-04 OTERO JOSE MANUEL Chief Operating Officer — 65,000 $0.00 $0
2026-02-04 TAMAYO LOUIS EDWARD Chief Financial Officer — 44,665 $0.00 $0
2025-11-18 TOWNSEND RICHARD NOLAN Chief Executive Officer — 1,127 $9.27 $10,447
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.65
Operating Revenue
0.00
0.00
0.00
-100.00%
0.65
Operating Expense
109.26
+3.30%
105.77
+54.37%
68.51
+12.02%
61.16
Research And Development
63.80
-13.89%
74.09
+39.45%
53.13
+8.07%
49.16
Selling General And Administration
45.46
+43.52%
31.68
+105.91%
15.38
+28.18%
12.00
General And Administrative Expense
45.46
+43.52%
31.68
+105.91%
15.38
+28.18%
12.00
Other Gand A
45.46
+43.52%
31.68
+105.91%
15.38
+28.18%
12.00
Total Expenses
109.26
+3.30%
105.77
+54.37%
68.51
+12.02%
61.16
Operating Income
-109.26
-3.30%
-105.77
-54.37%
-68.51
-13.23%
-60.51
Total Operating Income As Reported
-109.26
-3.30%
-105.77
-54.37%
-68.51
-13.23%
-60.51
EBITDA
-97.68
-1.54%
-96.19
-49.49%
-64.35
-10.86%
-58.04
Normalized EBITDA
-101.07
-5.06%
-96.19
-50.74%
-63.82
-9.95%
-58.04
Reconciled Depreciation
2.08
+3.85%
2.00
+8.63%
1.84
+60.96%
1.15
EBIT
-99.75
-1.59%
-98.20
-48.36%
-66.19
-11.83%
-59.19
Total Unusual Items
3.39
—
-0.53
—
Total Unusual Items Excluding Goodwill
3.39
—
-0.53
—
Special Income Charges
—
—
—
—
Net Income
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Pretax Income
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Net Non Operating Interest Income Expense
5.92
-20.40%
7.44
+179.56%
2.66
+115.72%
1.23
Interest Expense Non Operating
0.21
+50.36%
0.14
-33.17%
0.20
+125.27%
0.09
Net Interest Income
5.92
-20.40%
7.44
+179.56%
2.66
+115.72%
1.23
Interest Expense
0.21
+50.36%
0.14
-33.17%
0.20
+125.27%
0.09
Interest Income Non Operating
6.13
-19.12%
7.58
+164.35%
2.87
+116.38%
1.32
Interest Income
6.13
-19.12%
7.58
+164.35%
2.87
+116.38%
1.32
Other Income Expense
3.37
+37566.67%
-0.01
+98.34%
-0.54
-27050.00%
-0.00
Other Non Operating Income Expenses
-0.02
-100.00%
-0.01
+30.77%
-0.01
-550.00%
-0.00
Gain On Sale Of Security
3.39
—
-0.53
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Net Income From Continuing Operation Net Minority Interest
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Net Income From Continuing And Discontinued Operation
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Net Income Continuous Operations
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Normalized Income
-103.35
-5.10%
-98.33
-49.30%
-65.86
-11.11%
-59.28
Net Income Common Stockholders
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Diluted EPS
—
-3.09
+75.08%
-12.40
-426.51%
-2.36
Basic EPS
—
-3.09
+75.08%
-12.40
-426.51%
-2.36
Basic Average Shares
—
31.79
+493.67%
5.35
-78.73%
25.17
Diluted Average Shares
—
31.79
+493.67%
5.35
-78.73%
25.17
Diluted NI Availto Com Stockholders
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
268.69
+82.85%
146.94
+5.10%
139.81
Current Assets
188.39
+49.37%
126.12
+1.47%
124.29
Cash Cash Equivalents And Short Term Investments
181.77
+49.58%
121.52
+0.04%
121.47
Cash And Cash Equivalents
63.00
+79.93%
35.01
-71.17%
121.47
Other Short Term Investments
118.77
+37.30%
86.50
0.00
Prepaid Assets
—
—
2.83
Other Current Assets
6.62
+43.93%
4.60
+62.77%
2.83
Total Non Current Assets
80.30
+285.65%
20.82
+34.22%
15.51
Net PPE
8.86
-16.10%
10.56
-13.90%
12.26
Gross PPE
9.60
-12.99%
11.03
-12.74%
12.64
Accumulated Depreciation
-0.74
-56.33%
-0.47
-24.41%
-0.38
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.39
+0.00%
0.39
-42.90%
0.68
Other Properties
8.94
-13.81%
10.37
-11.49%
11.72
Leases
0.27
+0.00%
0.27
+10.12%
0.25
Investments And Advances
68.19
+872.49%
7.01
0.00
Long Term Equity Investment
3.39
0.00
—
Non Current Prepaid Assets
—
—
—
Other Non Current Assets
3.25
-0.12%
3.25
+0.00%
3.25
Total Liabilities Net Minority Interest
22.02
-26.85%
30.10
+14.57%
26.27
Current Liabilities
16.81
-26.43%
22.85
+32.53%
17.24
Payables And Accrued Expenses
9.99
-35.60%
15.52
+37.70%
11.27
Payables
4.86
-24.33%
6.42
+69.14%
3.79
Accounts Payable
4.86
-24.33%
6.42
+69.14%
3.79
Current Accrued Expenses
5.14
-43.55%
9.10
+21.75%
7.48
Pensionand Other Post Retirement Benefit Plans Current
4.07
-1.12%
4.11
+46.33%
2.81
Total Tax Payable
—
—
0.16
Current Debt And Capital Lease Obligation
2.67
+0.19%
2.67
+2.50%
2.60
Current Capital Lease Obligation
2.67
+0.19%
2.67
+2.50%
2.60
Current Deferred Liabilities
—
—
—
Current Deferred Revenue
—
—
—
Other Current Liabilities
0.07
-86.61%
0.55
-1.62%
0.55
Total Non Current Liabilities Net Minority Interest
5.21
-28.16%
7.25
-19.69%
9.03
Long Term Debt And Capital Lease Obligation
5.21
-28.16%
7.25
-19.69%
9.03
Long Term Capital Lease Obligation
5.21
-28.16%
7.25
-19.69%
9.03
Preferred Securities Outside Stock Equity
—
—
0.00
Stockholders Equity
246.67
+111.11%
116.84
+2.91%
113.53
Common Stock Equity
246.67
+111.11%
116.84
+2.91%
113.53
Capital Stock
0.01
+133.33%
0.00
+0.00%
0.00
Common Stock
0.01
+133.33%
0.00
+0.00%
0.00
Preferred Stock
—
0.00
0.00
Share Issued
73.00
+120.69%
33.08
+24.04%
26.67
Ordinary Shares Number
73.00
+120.70%
33.08
+24.13%
26.65
Treasury Shares Number
0.00
+0.00%
0.00
-82.69%
0.02
Additional Paid In Capital
626.62
+57.79%
397.13
+34.45%
295.37
Retained Earnings
-380.13
-35.68%
-280.17
-54.08%
-181.84
Gains Losses Not Affecting Retained Earnings
0.19
+282.52%
-0.10
0.00
Treasury Stock
0.02
+0.00%
0.02
0.00
Other Equity Adjustments
0.19
+282.52%
-0.10
—
Total Equity Gross Minority Interest
246.67
+111.11%
116.84
+2.91%
113.53
Total Capitalization
246.67
+111.11%
116.84
+2.91%
113.53
Working Capital
171.58
+66.14%
103.28
-3.53%
107.06
Invested Capital
246.67
+111.11%
116.84
+2.91%
113.53
Total Debt
7.89
-20.54%
9.92
-14.73%
11.64
Capital Lease Obligations
7.89
-20.54%
9.92
-14.73%
11.64
Net Tangible Assets
246.67
+111.11%
116.84
+2.91%
113.53
Tangible Book Value
246.67
+111.11%
116.84
+2.91%
113.53
Available For Sale Securities
64.80
+824.14%
7.01
—
Investmentin Financial Assets
64.80
+824.14%
7.01
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-98.56
-21.45%
-81.15
-36.40%
-59.50
-9.05%
-54.56
Cash Flow From Continuing Operating Activities
-98.56
-21.45%
-81.15
-36.40%
-59.50
-9.05%
-54.56
Net Income From Continuing Operations
-99.96
-1.66%
-98.33
-48.11%
-66.39
-12.01%
-59.28
Depreciation Amortization Depletion
2.08
+3.85%
2.00
+8.63%
1.84
+60.96%
1.15
Depreciation
2.08
+3.85%
2.00
+8.63%
1.84
+60.96%
1.15
Depreciation And Amortization
2.08
+3.85%
2.00
+8.63%
1.84
+60.96%
1.15
Other Non Cash Items
—
—
0.53
—
Stock Based Compensation
12.13
-2.74%
12.47
+309.92%
3.04
+70.86%
1.78
Operating Gains Losses
-3.41
—
—
—
Gain Loss On Investment Securities
-3.41
—
—
—
Change In Working Capital
-9.52
-448.66%
2.73
+84.14%
1.48
-17.25%
1.79
Change In Prepaid Assets
-2.00
-18.58%
-1.69
-270.71%
0.99
+152.46%
-1.89
Change In Payables And Accrued Expense
-6.01
-204.54%
5.75
+200.63%
1.91
-52.56%
4.03
Change In Accrued Expense
-4.45
-232.02%
3.37
+61.02%
2.09
-53.28%
4.48
Change In Payable
-1.56
-165.64%
2.38
+1421.11%
-0.18
+59.82%
-0.45
Change In Account Payable
-1.56
-165.64%
2.38
+1421.11%
-0.18
+57.75%
-0.43
Change In Other Working Capital
—
—
—
-0.05
Change In Other Current Liabilities
-1.50
-13.50%
-1.33
+6.55%
-1.42
-366.78%
-0.30
Investing Cash Flow
-90.25
+4.07%
-94.08
-56916.36%
-0.17
+81.69%
-0.90
Cash Flow From Continuing Investing Activities
-90.25
+4.07%
-94.08
-56916.36%
-0.17
+81.69%
-0.90
Net PPE Purchase And Sale
-0.40
+17.46%
-0.48
-318.26%
-0.12
+82.89%
-0.67
Purchase Of PPE
-0.40
+17.46%
-0.48
-318.26%
-0.12
+82.89%
-0.67
Capital Expenditure
-0.40
+17.46%
-0.48
-191.52%
-0.17
+81.69%
-0.90
Net Investment Purchase And Sale
-89.86
+4.00%
-93.60
0.00
—
Purchase Of Investment
-195.38
-108.75%
-93.60
0.00
—
Sale Of Investment
105.53
0.00
—
—
Net Intangibles Purchase And Sale
—
0.00
+100.00%
-0.05
+78.17%
-0.23
Purchase Of Intangibles
—
0.00
+100.00%
-0.05
+78.17%
-0.23
Financing Cash Flow
216.79
+144.20%
88.78
-14.47%
103.79
+54815.87%
0.19
Cash Flow From Continuing Financing Activities
216.79
+144.20%
88.78
-14.47%
103.79
+54815.87%
0.19
Net Issuance Payments Of Debt
-0.53
-30.00%
-0.41
-111.47%
3.58
+2293.25%
-0.16
Issuance Of Debt
—
0.00
-100.00%
4.00
0.00
Repayment Of Debt
-0.53
-30.00%
-0.41
+3.53%
-0.42
-160.74%
-0.16
Long Term Debt Issuance
—
0.00
-100.00%
4.00
0.00
Long Term Debt Payments
-0.53
-30.00%
-0.41
+3.53%
-0.42
-160.74%
-0.16
Net Long Term Debt Issuance
-0.53
-30.00%
-0.41
-111.47%
3.58
+2293.25%
-0.16
Net Common Stock Issuance
234.02
+146.38%
94.98
-5.26%
100.25
0.00
Common Stock Payments
0.00
+100.00%
-0.02
0.00
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.02
0.00
—
Proceeds From Stock Option Exercised
0.06
-87.98%
0.49
+862.75%
0.05
-84.64%
0.33
Net Other Financing Charges
-16.75
-166.42%
-6.29
-7210.47%
-0.09
—
Changes In Cash
27.98
+132.37%
-86.45
-295.90%
44.13
+179.84%
-55.27
Beginning Cash Position
38.27
-69.32%
124.72
+54.76%
80.59
-40.68%
135.86
End Cash Position
66.25
+73.12%
38.27
-69.32%
124.72
+54.76%
80.59
Free Cash Flow
-98.96
-21.22%
-81.63
-36.83%
-59.66
-7.57%
-55.46
Interest Paid Supplemental Data
0.10
-18.11%
0.13
-27.84%
0.18
+128.57%
0.08
Income Tax Paid Supplemental Data
—
—
0.00
0.00
Amortization Of Securities
0.11
+582.61%
-0.02
0.00
—
Change In Income Tax Payable
—
—
-0.35
-1486.36%
-0.02
Change In Tax Payable
—
—
-0.35
-1486.36%
-0.02
Common Stock Issuance
234.02
+146.34%
95.00
-5.24%
100.25
0.00
Issuance Of Capital Stock
234.02
+146.34%
95.00
-5.24%
100.25
+501155.00%
0.02
Net Preferred Stock Issuance
—
—
0.00
-100.00%
0.02
Preferred Stock Issuance
—
—
0.00
-100.00%
0.02
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category